Form 4: Corcept CDO Sells Shares After Option Exercise

Corcept Therapeutics' Chief Development Officer, William Guyer, sold 35,007 shares of common stock after exercising stock options, pursuant to a pre-arranged 10b5-1 plan.

Summary

• William Guyer, Chief Development Officer of Corcept Therapeutics Inc. (CORT), engaged in a pre-planned transaction on August 8, 2025.
• Exercised 35,007 stock options at an exercise price of $21.65 per share.
• Immediately sold 35,007 shares of common stock at a price of $71.77 per share.
• The sale was executed under a Rule 10b5-1 plan adopted on November 27, 2024.
• Following these transactions, William Guyer's direct beneficial ownership of common stock is 5,487 shares.
• He retains 350,000 stock options.

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale executed under a pre-planned 10b5-1 program, which typically reduces the negative perception associated with insider selling. The executive realized a substantial gain from the option exercise and subsequent sale.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating a pre-scheduled transaction rather than a reaction to recent non-public information.
• The sale price of $71.77 per share is significantly higher than the exercise price of $21.65, indicating a substantial gain for the insider.

Negatives

• An insider sale, even if pre-planned, reduces the insider's direct equity stake in the company.
• The insider's direct beneficial ownership of common stock decreased from an implied 40,494 shares to 5,487 shares.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

Industry Context

This filing details a routine insider transaction by an executive, which is specific to the individual's financial planning and does not directly reflect broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: May view the sale as a routine, pre-planned event, or potentially as a slight reduction in insider alignment, though the 10b5-1 plan mitigates the latter.

Key Dates

Recommendation

This Form 4 filing details a pre-scheduled insider transaction (option exercise and sale) by a Chief Development Officer. The transaction was executed under a Rule 10b5-1 plan, which suggests it's part of the executive's long-term financial planning rather than a reaction to new material information. While it represents a reduction in the insider's direct share ownership, the pre-planned nature and the executive's continued holding of a significant number of options (350,000) mean it's unlikely to signal a negative outlook on the company's future. Therefore, it does not provide a strong signal for a "buy" or "sell" recommendation, leading to a "hold" stance based solely on this filing.

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Trading, Stock Option Exercise, Share Sale, William Guyer, 10b5-1 Plan, Chief Development Officer